The MEB actively co-operates with health care providers to promote the proper use of medicines.
- Patient information leaflet
- Risks of excipients in medicines
- Generic medicines
- Off-label use
- Usage patents, SmPCs and patient information leaflets
In-use shelf life to be listed on packaging of over-the-counter medicinal products
The Medicines Evaluation Board (MEB) wants manufacturers of over-the-counter medicinal products to list the in-use shelf life...
Narrow-spectrum penicillin no longer available: concerning development
The Medicines Evaluation Board (MEB) deems it extremely concerning that the antibiotics Sodium Penicillin G 1,000,000 IU,...
Clarification of stance on biological and biosimilar medicines
In March 2015, the Medicines Evaluation Board (MEB) updated its stance about biosimilar medicines. Based on reactions from and...
MEB confirms current legal status of supply ibuprofen 200 mg
The Medicines Evaluation Board (MEB) has evaluated whether the recent European review of the adverse events on heart and blood...
MEB research: how do healthcare providers experience medicines safety information?
The Medicines Evaluation Board (MEB) is researching the experience of healthcare providers with information relating to safety...